We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current 0LB2 market cap is 3.04B. The company's latest EPS is USD 1.3377 and P/E is 23.97.
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 520.4M | 586.31M | 667.75M | 609.04M | 667.93M |
| Operating Income | 173.7M | 86.03M | 46.12M | -5.27M | 81.67M |
| Net Income | 126.95M | 53.42M | 60.71M | 1.32M | 73.87M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.5B | 1.69B | 1.7B | 1.28B | 1.37B |
| Total Liabilities | 759.24M | 873.3M | 816.3M | 356.16M | 332.34M |
| Total Equity | 744.86M | 815.85M | 886.2M | 921.52M | 1.04B |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 138.4M | 127.13M | 116.83M | 111.09M | 171.95M |
| Investing | -34.7M | -81.91M | -216.66M | 268.73M | -189.87M |
| Financing | 3.56M | -130.42M | -10.48M | -397.88M | 12.19M |
| Market Cap | 3.04B |
| Price to Earnings Ratio | 23.97 |
| Price to Sales Ratio | 2.65 |
| Price to Cash Ratio | 25.53 |
| Price to Book Ratio | 1.71 |
| Dividend Yield | - |
| Shares Outstanding | 55.22M |
| Average Volume (1 week) | 11 |
| Average Volume (1 Month) | 222 |
| 52 Week Change | 0.00% |
| 52 Week High | 55.00 |
| 52 Week Low | 55.00 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Supernus Pharmaceuticals Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.supernus.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
